Tel: 1-631-626-9181 (USA)   44-207-097-1828 (Europe)

CBpromise   

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER

c14orf101

Bookmark and Share
Official Full Name
chromosome 14 open reading frame 101
Synonyms
C14ORF101; chromosome 14 open reading frame 101; 20185; ENSG00000070269; 14q22.3; FLJ20392; UPF0679 protein C14orf101

Recent Research Progress

Chromosome 14 open reading frame 10 (C14orf101), also known as transmembrane protein 260 (TMEM260), is conserved among chimpanzees, rhesus monkeys, dogs, cattle, mice, rats, chickens and zebrafish. However, functional studies of this gene have not been reported so far. The results of the current study indicate that the MicroRNAs (miRNAs)-binding single nucleotide polymorphisms (SNPs) of C14orf101 have an impact on cancer development, such as Human non-Hodgkin lymphoma (NHL),Gastric cancer (GC),Colorectal cancer (CRC) and Hepatocellular carcinoma (HCC).

A polymorphism at the microRNA binding site in the 3'-untranslated region (UTR) of C14orf101 is associated with NHL overall survival

NHL is the fifth most common cancer in the world and its incidence is increasing. NHL is a heterogeneous disorder of the tumor with varying bioinvasiveness and clinical processes. Many tumor biomarkers have been identified as predictors of NHL survival, but are rarely used for routine clinical examination. SNPs located at the miRNA binding sites, involving RYR3 (rs1044129), C14orf101 (rs4901706), KIAA0423 (rs1053667) and GOLGA7 (rs11337), were evaluated for their predictive value for NHL survival, and rs4901706 of C14orf101 was identified as being connected with NHL overall survival by univariate and multivariate analyses. In conclusion, it was found that SNPs in the C14orf101 miRNA binding site are independent prognostic markers of overall survival of NHL. The analysis of genetic polymorphisms in miRNA binding sites may help to identify subgroups of patients with poor prognosis and may help to improve treatment decisions for patients with NHL.

C14orf101 miRNA binding site SNP in the 3'-UTR, which has the ability to predict GC risk

GC is associated with high morbidity and mortality. It is the fourth most common type of cancer and one of the leading causes of cancer-related mortality worldwide. Some studies have shown that the rs4901706 SNP of the C14orf101 gene may be a risk biomarker for GC. Furthermore, the A to G conversion of rs4901706 in the 3'-UTR of C14orf101 can result in the disruption of the A:T bond at the miRNA binding site, so as to altering the affinity of C14orf101 for binding to miRNA. This may regulate the expression of the genes, thereby initiating GC carcinogenesis. Therefore, the binding of miRNA to C14orf101 and the role of C14orf101 in the expression of proliferation, invasion and apoptosis of gastric cancer cells in future studies should be identified, and valuable for the prevention of GC.

In summary, a number of studies have shown that the rs4901706 SNP in the 3'-UTR of C14orf101 is associated with a variety of cancer risks as a potential miRNA binding site, although the miRNA binding to this site was not specified. Consequently, further research on the rs4901706 SNP is valuable.

References:

  1. Bo Yang, et al. A polymorphism at the microRNA binding site in the 3'-untranslated region of C14orf101 is associated with non-Hodgkin lymphoma overall survival. Cancer Genetics, 2014, 207: 141-146.
  2. CUIJU WANG, et al. A polymorphism at the microRNA binding site in the 3'-untranslated region of C14orf101 is associated with the risk of gastric cancer development. Experimental And Therapeutic Medicine, 2016, 12: 1867-1872 .
  3. Peng et al. A polymorphism at the microRNA binding site in the 3′-untranslated region of RYR3 is associated with outcome in hepatocellular carcinoma. OncoTargets and Therapy, 2015, 8: 2075–2079.
  4. Yue Zhao, et al. Single nucleotide polymorphisms at the microRNA-binding site of KIAA0423 are associated with colorectal cancer. Biotechnology & Biotechnological Equipment, 2016, 30(6): 1163-1167.